RecruitingCADASIL
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
Sponsor: University of Wisconsin, Madison
You may qualify if…
- ✓ 1. Must be at least 18 years old
- ✓ 2. Positive NOTCH3 genetic testing; OR a positive skin biopsy; OR a willingness to have a NOTCH3 genetic test completed prior to enrolling AND are at-risk for, or diagnosed clinically with, CADASIL
- ✓ 3. Willing to commit to three in-person visits (a baseline visit, an 18-month follow-up, and a 36-month follow-up) and to remote visits as needed by phone, email, mail or internet
- ✓ 4. Willing to provide documentation of all current medications to study team
- ✓ a. All medications will be allowed throughout the course of study. Documentation of medications will be used for analyses to assess potential impact of medications on study outcomes.
- ✓ 5. Willing and able to undergo an MRI scan and blood draw at each in-person visit
- ✓ 6. Must have a designated "study companion"
- ✓ a. A "study companion" is someone who knows the participant well (has greater than or equal to 3 hours/month of contact with the CADASIL participant) and can provide additional information to the study team (either remotely or in-person).
You may not qualify if…
- ✕ 1. History of severe learning disability, intellectual disability, or other neurological disease or event not attributable to CADASIL
- ✕ 2. History of serious alcohol or drug abuse within the past year
- ✕ 3. Unwilling to undergo NOTCH3 genetic testing if there is no test on file
Where it's recruiting
California
Los Angeles · San Francisco
Colorado
Denver
Georgia
Atlanta
Illinois
Chicago
New York
New York
Oregon
Portland
Rhode Island
Providence
Texas
Houston · San Antonio
Utah
Salt Lake City
Washington
Seattle
Source: ClinicalTrials.gov · NCT05677880 · last updated 2026-01-15